Oldfield Vicki, Keating Gillian M, Plosker Greg
Adis International Limited, Auckland, New Zealand.
Drugs. 2005;65(8):1139-60. doi: 10.2165/00003495-200565080-00007.
Enfuvirtide (Fuzeon), a fusion inhibitor, is indicated in combination with other antiretroviral agents in the treatment of HIV infection in treatment-experienced adults and children aged >6 years. The addition of subcutaneous enfuvirtide to an optimised antiretroviral background regimen improved the virological and immunological response in treatment-experienced HIV-infected patients in the two large, well designed TORO (T-20 vs Optimised Regimen Only) trials. Although injection-site reactions occurred almost universally in enfuvirtide recipients, they were rarely treatment-limiting. Enfuvirtide was otherwise generally well tolerated. The challenge for clinicians is in determining the appropriate timing for enfuvirtide initiation, which requires consideration of the likelihood of a better virological response with the construction of an active background regimen versus the potential for a low rate of adherence to therapy in patients in the early stages of treatment and/or disease development. Enfuvirtide is a novel antiretroviral that is effective in HIV-infected patients whose treatment options are limited by multi-class antiretroviral resistance.
恩夫韦肽（福泽昂）是一种融合抑制剂，适用于与其他抗逆转录病毒药物联合，用于治疗有治疗经验的成人和6岁以上儿童的HIV感染。在两项设计良好的大型TORO（T - 20与仅优化治疗方案）试验中，在优化的抗逆转录病毒背景治疗方案中添加皮下注射恩夫韦肽，改善了有治疗经验的HIV感染患者的病毒学和免疫学反应。虽然接受恩夫韦肽治疗的患者几乎普遍出现注射部位反应，但这些反应很少导致治疗受限。恩夫韦肽在其他方面总体耐受性良好。临床医生面临的挑战在于确定开始使用恩夫韦肽的合适时机，这需要考虑构建积极的背景治疗方案时获得更好病毒学反应的可能性，以及在治疗早期和/或疾病发展阶段患者治疗依从性低的可能性。恩夫韦肽是一种新型抗逆转录病毒药物，对因多类抗逆转录病毒耐药而治疗选择受限的HIV感染患者有效。
